ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2295건의 자료가 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2274 | Withdrawn | A Clinical Trial to Evaluate the Efficacy of RUTI® to Reduce the Severity of SARS-CoV-2 Infection (COVID-19) | COVID-19 | Biological: RUTI® vaccine Biological: Placebo |
Phase 3 | PT. Innovative Pharma Solutions, Archivel Farma S.L., RUTI Immunotherapeutics S.L. | INDUSTRY | 0 | All | 18 Years | |
| 2273 | Active, not recruiting | A Clinical Trial to Evaluate the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for COVID-19 | COVID-19 | Biological: low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell) Biological: high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell) Biological: placebo |
Phase 2 | National Vaccine and Serum Institute, China, Lanzhou Institute of Biological Products Co., Ltd, Beijing Zhong Sheng Heng Yi Pharmaceutical Technology Co., Ltd., Zhengzhou University | INDUSTRY | 3100 | All | 3 Years | Ning ling Center for Disease Control and Prevention, Shang Qiu, He Nan, China |
| 2272 | Completed | A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19 | COVID-19 | Biological: CpG 1018/Alum-adjuvanted SCB-2019 vaccine Biological: Placebo; 0.9% saline Biological: SCB-2019 vaccine Biological: SCB-2019 vaccine for Placebo |
Phase 3 | Clover Biopharmaceuticals AUS Pty Ltd, Coalition for Epidemic Preparedness Innovations, International Vaccine Institute | INDUSTRY | 31454 | All | 12 Years | Anima, Alken, Belgium Hospital Erasme, Bruxelles, Belgium Private Practice RESPISOM Namur, Namur, Belgium Instituto D'OR de Pesquisa e Ensino, Rio de Janeiro, Rio Do Janeiro, Brazil Instituto Atena de Pesquisa Clinica, Natal, Rio Grande Do Norte, Brazil CPCLIN - Centro de Pesquisas Clinicas de Natal, Natal, Rio Grande Do Norte, Brazil Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil Hospital da Universidade Federal de Santa Maria CEP/UFSM, Santa Maria, Rio Grande Do Sul, Brazil Centro de Atencion e investigacion Medica S.A.S, CAIMED S.A.S - sede, Acacias, Acacias, Colombia Centro de Atencion e investigacion Medica S.A.S, CAIMED S.A.S - sede Aguazul, Aguazul, Colombia Clinica de la Costa Ltda, Barranquilla, Colombia Fundacion Hospital Universitario del Norte, Barranquilla, Colombia Centro de Atencion e investigacion Medica S.A.S, CAIMED S.A.S - sede, Bogota D.C., Bogota, Colombia Policlinico Social del Norte, Bogota, Colombia Centro de Estudios en Infectologia Pediatrica S.A.S. - CEIP S.A.S., Cali, Colombia IPS Medicos Internistas de Caldas SAS, Manizales, Colombia Centro de Atencion e investigacion Medica S.A.S, CAIMED S.A.S - sede, Yopal, Yopal, Colombia De La Salle Medical and Health Sciences Institute, Dasmarinas, Cavite, Philippines Las Pinas Doctors Hospital, Las Pinas, Philippines Tropical Disease Foundation, Makati, Philippines Manila Doctors Hospital, Manila, Philippines Asian Hospital and Medical Center, Muntinlupa, Philippines University of the Philippines Manila - Philippine General Hospital, Pasay, Philippines UERM Memorial Medical Center, Quezon City, Philippines University of the East Ramon Magsaysay Memorial Medical Center, Quezon City, Philippines FEU-NRMF Medical Center, Quezon City, Philippines St. Luke's Medical Center, Taguig, Philippines Wits Clinical Research, Johannesburg, Gauteng, South Africa DJW Research, Krugersdorp, Gauteng, South Africa Soweto Clinical Trials Centre, Soweto, Gauteng, South Africa Dr JM Engelbrecht Trial Site, Somerset West, Western Cape, South Africa |
| 2271 | Completed | A Dose Escalation and Dose Expansion Study of NOX66 in the Treatment of COVID-19 | Covid19 | Drug: NOX66 | Phase 1 | Noxopharm Limited | INDUSTRY | 41 | All | 18 Years | Institute of Emergency Medicine, Chisinau, Moldova, Republic of |
| 2270 | Completed | A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection | Coronavirus | Drug: Fluvoxamine Drug: Placebo |
Phase 2 | Washington University School of Medicine | OTHER | 152 | All | 18 Years | BJC, Belleville, Illinois, United States Washington University School of Medicine, Saint Louis, Missouri, United States |
| 2269 | Completed | A First-In-Human Phase 1b Study of AmnioPul-02 in COVID-19 / Other LRTI | COVID-19 | Drug: AmnioPul-02 | Phase 1 | Amniotics AB | INDUSTRY | 6 | All | 18 Years ~ 80 Years | Infection clinic, Malmo, Skane, Sweden |
| 2268 | Recruiting | A Global Multi-center Clinical Study of SARS-CoV-2 mRNA Vaccine for the Prevention of COVID-19 | SARS-CoV-2 | Biological: LVRNA009 Other: 0.9%NaCl |
Phase 3 | AIM Vaccine Co., Ltd., AIM Innovation Biotechnology (Shanghai) Co., Ltd, Ningbo Rongan Biological Pharmaceutical Co., Ltd., LiveRNA Therapeutics Inc. | INDUSTRY | 34000 | All | 18 Years | KEMRI CRDR Research Annex, Siaya Country Referral Hospital, Siaya, Kenya |
